Abstract 240P
Background
TACE combined with targeted therapy and immunotherapy represents a potentially effective treatment for intermediate and advanced HCC. This study aims to compare the efficacy and safety of TACE combined with tislelizumab and TKIs versus TACE among this population.
Methods
Data from 62 patients (pts) with intermediate and advanced HCC from June 2017 to September 2023 were analyzed retrospectively. The pts were divided into two groups: group 1 (30 pts) received TACE supplemented with tislelizumab and TKIs (76.7% pts receiving Lenvatinib), and group 2 (32 pts) underwent TACE. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
There were no significant differences in baseline parameters between two groups (P＞0.05). The average follow-up was 10.7 months(m), median PFS were 11.1 m (95%CI, 9.6-NA) in group 1 and 3.8 m (95%CI, 0.9-6.7) in group 2 (hazard ratio [HR], 1.97 [95CI, 1.08-3.60], P=0.027). The 12-m and 18-m OS rates were higher in group 1 than group 2 (75% vs 51%; 68% vs 47%). The ORR and DCR were higher in group 1 than group 2 (ORR, 46.7% [CR 4, PR 10] vs 18.8% [CR 2, PR 4], P=0.029; DCR, 96.7% vs 75.0%, P=0.027; mRECIST). 4 pts (13.3%) in group 1 received curative treatment after reaching CR or PR, including 2 curative hepatic resection, and 2 ablation. Adverse event (AE) rates were 86.7% (group 1) and 81.3% (group 2) respectively, while grade 3 or higher AEs occurred at rates of 10.0% in group 1 in total, with none observed in group 2. Table: 240P
Baseline characteristics
| Characteristics | TACE+Tislelizumab+TKIs (n=30) | TACE (n=32) | P value |
| Median age (range), years | 55 (30-75) | 60.5 (36-78) | 0.409 |
| Male, n(%) | 28 (93.3) | 29 (90.6) | 1.000 |
| BCLC stage, n(%), B/C | 16 (53.3)/14 (46.7) | 16 (50.0)/16 (50.0) | 0.805 |
| ECOG PS, n(%), 0/1 | 26 (86.7)/4 (13.3) | 27 (84.4)/5 (15.6) | 1.000 |
| Child-Pugh, n(%), A/B | 19 (63.3)/11 (36.7) | 24 (75.0)/8 (25.0) | 0.411 |
| MVI present, n(%) | 11 (36.7) | 16 (50.0) | 0.317 |
| EHS present, n(%) | 7 (23.3) | 7 (21.9) | 1.000 |
| Median number of TACE | 3 | 2 | 0.399 |
Conclusions
Compared to TACE, TACE combined with tislelizumab and TKIs is expected to be a safe and effective treatment for intermediate and advanced HCC. The combined therapy could be regarded as a considerable option for conversion strategy in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.